Heidelberg, Germany – June 6, 2025 – AaviGen GmbH, a preclinical stage biotechnology company focused on the development of curative gene therapies for cardiovascular and cardiopulmonary diseases, is pleased to announce the successful completion of the German Accelerator U.S. Market Access Life Sciences Program, marking a major milestone in our global expansion and innovation journey.
German Accelerator offers programs to help German startups scale globally by providing tailored support, expert mentorship, and valuable industry connections. German Accelerator is run by Start2 Group and is financed by the Federal Ministry for Economic Affairs and Energy (BMWE). We thank Marc Filerman – Managing Partner, Life Sciences, Start2 Group, ranked among the top 3 start-up hubs in Europe as well as the #1 in Europe for Alumni Track Record according to the most recent rankings by the Financial Times.
We also thank the German Federal Ministry for Economic Affairs and Energy (BMWE) for funding the German Accelerator and for its vision in connecting promising life science start-ups with U.S.-based expertise.
Over the past six months, the program has provided AaviGen with unparalleled access to expert guidance, networks, and strategic insights essential for advancing our cardiovascular gene therapy pipeline. We extend our sincere gratitude to Maurice Lee, Program Director, Life Sciences at Start2 Group for expertly stewarding us through the program and to our outstanding mentors—Alan Horsager, Neema Mayhugh, and especially our Lead Mentor, Will Adams—for their invaluable contributions.
We are also pleased to share that Will Adams will be joining the AaviGen Advisory Board. His continued involvement will be instrumental as we accelerate our efforts to bring transformative gene therapies to patients suffering from cardiovascular diseases.
In these uncertain geopolitical times, the AaviGen leadership team remains steadfast in its mission: to navigate complex global landscapes and build enduring transatlantic bridges—so we can better serve unmet needs in cardiovascular disease.
About AaviGen
AaviGen was founded in 2019 on the understanding that successful gene therapy requires optimized delivery of therapeutic targets to the diseased heart. AaviGen’s scientific approach is documented in numerous peer-reviewed scientific publications and validated by its founders’ track record in scientific innovations for the diagnosis and treatment of cardiac diseases, including gene therapy medicinal products. For more information, please see: www.aavigen.com
AaviGen Investor and Media Contact
Prof. Dr. Marc Lerchenmüller, Chief Financial Officer and Managing Director
AaviGen, Heidelberg, Germany
T: +49 6221 568900
M: +49 151 51646589
marc.lerchenmueller@aavigen.com
AaviGen’s Forward-Looking Statements
This press release contains statements that constitute “forward looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions, or projections of the company regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the company’s strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” or “expect,” “may,” “will,” “would,” “could,” “potential,” “intend,” or “should,” the negative of these terms or similar expressions. Forward looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company’s performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company’s industry, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.